Medtronic

Surgical heart valves

2022 coding and reimbursement

This information is provided for your consideration. It is the provider’s responsibility to determine and submit appropriate codes, modifiers, and charges for the services rendered.

Surgical valves hospital coding (select codes related to Medtronic surgical valves)

<table>
<thead>
<tr>
<th>Valve product</th>
<th>Composition</th>
<th>Site</th>
<th>ICD-10 PCS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aortic and mitral positions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avalus™ Bioprosthesis</td>
<td>Bioprosthesis (stented tissue valve)</td>
<td>Aortic only</td>
<td>02RFO8Z (aortic)</td>
</tr>
<tr>
<td>Mosaic™, Mosaic Ultra™</td>
<td>Bioprosthesis (stented tissue valve)</td>
<td>Aortic or mitral</td>
<td>02RFO8Z (aortic) 02RGO8Z (mitral)</td>
</tr>
<tr>
<td>Hancock™ II, Hancock II Ultra™</td>
<td>Bioprosthesis (stented tissue valve)</td>
<td>Aortic or mitral</td>
<td>02RFO8Z (aortic) 02RGO8Z (mitral)</td>
</tr>
<tr>
<td>Medtronic Open Pivot™</td>
<td>Mechanical</td>
<td>Aortic or mitral</td>
<td>02RFOJZ (aortic) 02RGOJZ (mitral)</td>
</tr>
</tbody>
</table>

Valve product                      Composition                Site ICD-10 PCS

Aortic root – for replacement of malfunctioning native or prosthetic aortic valves with the option of aortic root replacement

| Freestyle™ Aortic Root Bioprosthesis | Bioprosthesis (stentless tissue valve) | Aortic valve only (with aortic root) | 02RF08Z for aortic valve replacement If ascending aorta is excised and replaced with a synthetic graft, use additional code 02RWOJZ |

Medtronic CardioVascular Reimbursement Hotline: 1-866-616-8400
## Surgical valves payment

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Description</th>
<th>Relative weight</th>
<th>Medicare National Unadjusted Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>216</td>
<td>Cardiac valve and oth maj cardiothoracic proc w card cath w MCC</td>
<td>10.0393</td>
<td>$66,202</td>
</tr>
<tr>
<td>217</td>
<td>Cardiac valve and oth maj cardiothoracic proc w card cath w CC</td>
<td>6.4835</td>
<td>$42,754</td>
</tr>
<tr>
<td>218</td>
<td>Cardiac valve and oth maj cardiothoracic proc w card cath w/o CC/MCC</td>
<td>6.1093</td>
<td>$40,287</td>
</tr>
<tr>
<td>219</td>
<td>Cardiac valve and oth maj cardiothoracic proc w/o card cath w MCC</td>
<td>8.0576</td>
<td>$53,134</td>
</tr>
<tr>
<td>220</td>
<td>Cardiac valve and oth maj cardiothoracic proc w/o card cath w CC</td>
<td>5.4053</td>
<td>$35,644</td>
</tr>
<tr>
<td>221</td>
<td>Cardiac valve and oth maj cardiothoracic proc w/o card cath w/o CC/MCC</td>
<td>4.5799</td>
<td>$30,201</td>
</tr>
</tbody>
</table>


### Reimbursement disclaimer

Medtronic does not represent or guarantee that this information is complete, accurate, or applicable to any particular patient or third-party payer. Medtronic disclaims all liability for any consequence resulting from reliance on this document. The final decision of billing for any service must be made by the healthcare provider considering the medical necessity of the service furnished as well as the requirements of third-party payers and any local, state, or federal laws and regulations that apply. Medtronic is providing this information in an educational capacity with the understanding that Medtronic is not engaged in rendering accounting, or other professional services. Medtronic encourages all healthcare providers to consult with their own advisors regarding coding and payment. All Medicare rates displayed in this document reflect the "national unadjusted" amounts inclusive of beneficiary cost-sharing and do not reflect any additional payment adjustments, such as the 2% sequester reduction mandated by the Budget Control Act of 2011 or the 4% PAYGO reduction triggered by the American Rescue Plan in December 2020. Please note that on December 10, 2021, legislation was enacted to delay the 2% sequestration for three months (January 1–March 31, 2022), followed by a reduction of 1% for three months (April 1–June 30, 2022). The full 2% sequestration cut will go back into effect on July 1, 2022. The 4% PAYGO reduction was postponed through January 1, 2023. Medtronic doesn’t offer products with approved indications for all procedures listed. For more information, contact the Cardiovascular Health Economics, Policy & Reimbursement Team.
**Mosaic™ Bioprosthesis**

**Indications:**
For the replacement of malfunctioning native or prosthetic aortic and/or mitral heart valves.

**Contraindications:**
None known.

**Warnings/precautions/adverse events:**
Accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). Adverse events can include: angina, cardiac dysrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, infection other than endocarditis, transvalvular or paravalvular leak, myocardial infarction, nonstructural valve dysfunction (leaflet entrapment/impingement, obstructive pannus ingrowth, suture dehiscence, inappropriate sizing or positioning, or other), periocardial effusion or tamponade, prosthetic regurgitation, prosthesis stenosis, prosthesis thrombosis, stroke, structural valve deterioration (calcification, leaflet tear or perforation, or other), thromboembolism, tissue dehiscence, and transient ischemic attack. These complications could lead to reoperation, explant of the bioprosthesis, permanent disability, or death.

**Caution:** Federal law (USA) restricts this device to sale by or on the order of a physician.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use. For countries that use eIFUs, consult instructions for use at medtronic.com/manuals (opens new window). Note: Manuals can be viewed using a current version of any major internet browser.

**Hancock™ II and Hancock II Ultra™ Bioprostheses**

**Indications:**
For patients who require replacement of their native or prosthetic aortic and/or mitral valves.

**Contraindications:**
None known.

**Warnings/precautions/adverse events:**
Accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). Adverse events can include: angina, cardiac dysrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, transvalvular or paravalvular leak, myocardial infarction, nonstructural dysfunction, stroke, structural deterioration, thromboembolism, or valve thrombosis.

For additional information, please refer to the Instructions for Use provided with the product.

**Caution:** Federal law (USA) restricts this device to sale by or on the order of a physician.

**Open Pivot™ mechanical heart valve**

**Indications:**
The Medtronic Open Pivot™ Heart Valve is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic or mitral valves.

**Contraindications:**
The Medtronic Open Pivot Heart Valve is contraindicated in patients unable to tolerate anticoagulation therapy.

**Potential adverse events:**
Adverse events potentially associated with the use of prosthetic heart valves include: cardiac dysrhythmias, death, leaflet entrapment/impingement, endocarditis, hemolysis, anticoagulant-related hemorrhage, transvalvular or paravalvular leak, prosthesis thrombosis, structural deterioration, valve thromboembolism.

**Caution:** Federal Law restricts this device to sale by or on the order of a physician or properly licensed practitioner. Refer to the Instructions For Use packaged with each valve for a complete listing of warnings and precautions.

**Freestyle™ Aortic Root Bioprosthesis**

**Indications:**
For the replacement of malfunctioning native or prosthetic aortic valves with the option of aortic root replacement.

**Contraindications:**
None known.

**Warnings/precautions/adverse events:**
Accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). Adverse events can include: cardiac dysrhythmias, death, endocarditis, hemolysis, hemorrhage, transvalvular or paravalvular leak, nonstructural dysfunction, structural deterioration, thromboembolism, valve thrombosis, or intracapsule hematoma. For additional information, please refer to the Instructions For Use provided with the product.

**Caution:** Federal law (USA) restricts this device to sale by or on the order of a physician.

---

**Medtronic CardioVascular Reimbursement Hotline:** 1-866-616-8400

medtronic.com